Mesoblast Limited has announced new data presented at the February 2026 meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for Blood and Marrow Transplant Research (CIBMTR). The results showed that Ryoncil® (remestemcel-L-rknd) achieved similarly high survival outcomes in steroid-refractory acute graft-versus-host disease (SR-aGvHD) when used in both children and adults, regardless of whether it was used as a second or third line treatment, and in patients who were either naive or resistant to ruxolitinib. Ryoncil® is currently the only FDA-approved mesenchymal stromal cell product for any indication and is approved for children under age 12 with SR-aGvHD. Mesoblast plans to initiate a pivotal trial to evaluate early use of Ryoncil® as a second-line treatment in adults with severe SR-aGvHD, following protocol approval by the central Institutional Review Board. If successful, this trial may support label extension for adult use. The presented results highlight the importance of early treatment initiation with Ryoncil® to maximize the likelihood of completing a full treatment course and improving survival outcomes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9653385-en) on February 11, 2026, and is solely responsible for the information contained therein.